RECRUITING

Drug Discovery for Parkinson's With Mutations in the GBA Gene

Talk to us

Conditions

Parkinson DiseaseGaucher DiseaseHealthyGBA Gene Mutation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.

Official Title

Drug Discovery for Parkinson's With Mutations in the GBA Gene

Quick Facts

Study Start:2022-07-15
Study Completion:2025-07-15
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05536388

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 18 years or older.
  2. * Diagnosis of Parkinson's disease, Gaucher disease, or healthy control.
  3. * Must provide written informed consent unless physical limitations preclude signing.
  1. * For skin samples collected specifically for this study: history of keloid formation, coagulation disorder, allergy to the anesthetic, or anticoagulation use that precludes sample collection.
  2. * For blood samples collected specifically for this study: coagulation disorder or other medical condition(s) that increases the risks associated with blood collection.
  3. * For all prospective sample collections: Subjects who refuse to adhere to NYSCF's and/or a collection site's safety protocols will be excluded. Subjects with an AIDS diagnosis and CD4 count of less than 200 cells per microliter (mcL) of blood will be excluded due to increased risk of infection.

Contacts and Locations

Study Contact

Becca Wood
CONTACT
212-927-1801
clinicalresearch@nyscf.org

Principal Investigator

Laura Andres-Martin
PRINCIPAL_INVESTIGATOR
New York Stem Cell Foundation Research Institute

Study Locations (Sites)

The New York Stem Cell Foundation Research Institute
New York, New York, 10019
United States

Collaborators and Investigators

Sponsor: New York Stem Cell Foundation Research Institute

  • Laura Andres-Martin, PRINCIPAL_INVESTIGATOR, New York Stem Cell Foundation Research Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-07-15
Study Completion Date2025-07-15

Study Record Updates

Study Start Date2022-07-15
Study Completion Date2025-07-15

Terms related to this study

Keywords Provided by Researchers

  • Parkinson Disease
  • GBA Gene Mutation

Additional Relevant MeSH Terms

  • Parkinson Disease
  • Gaucher Disease
  • Healthy
  • GBA Gene Mutation